Jul, 2012

U.S.A.
News / Therapeutic Area News
Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
Astellas Pharma Inc. ("Astellas"; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Fujita Health University (Aichi, President: Yoshikazu Kurosawa)...
Read More
U.S.A.
News / Therapeutic Area News
Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy
San Francisco, CA and Tokyo – July 24, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...
Read More
U.S.A.
News / Therapeutic Area News
Addition of Tarceva® (erlotinib) to Nexavar® (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Wayne, NJ, South San Francisco, CA and Tokyo, Japan – July 23, 2012 – Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. (TSE: 4503)...
Read More

Jun, 2012

U.S.A.
News / Therapeutic Area News
Full Prescribing Information for Myrebetrio (mirabegron) Extended Release Tablets
Full Prescribing Information for Myrebetrio (mirabegron) Extended Release Tablets
Read More
U.S.A.
News / Therapeutic Area News
FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and...
Read More